● TIER 3 — Information onlyGRADE BGH secretagogues & GH axis
MK-677 (ibutamoren) — non-peptide
Oral GH secretagogue. Research verification: Yes (TGA pending). 2 human study record(s) in the FitClinicMD studies database.
GOALS · Muscle / body composition · Sleep
FDA status
Not approved.
Compounding (503A/503B)
503A and 503B Category 2 (CHF signal)
DEA
Not controlled.
WADA (sport)
S2.2.4 GH-releasing factors: GHRH & analogues (CJC-1295, sermorelin, tesamorelin), GHS (ibutamoren, ipamorelin), GHRPs (GHRP-2/6, hexarelin)
Mechanism
Oral ghrelin mimetic; t½ ~24 h.
Human evidence · 2
Hip fracture trial terminated early for CHF signal. MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: a multicenter, randomized, placebo-controlled phase IIb study.
Healthy older adults n=65, 2 y: ↑GH/IGF-1, fat-free mass; no strength/function gain. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial.
Reference only. This page summarizes publicly available regulatory and research information about MK-677 (ibutamoren) — non-peptide. It is not a prescription, an endorsement, or an offer to dispense, and regulatory status can change. Clinicians should verify current status before prescribing or compounding.